Report Highlights

U.S. Active B12 Test Market: Market Overview

The U.S. active B12 test market is defined by its transition from conventional total cobalamin measurement toward holotranscobalamin (holoTC) assays, which identify functional B12 deficiency at least four to six weeks earlier than standard serum B12 panels. The market generated USD 312.4 million in 2024, driven primarily by large academic medical centres, national reference laboratories such as Quest Diagnostics and LabCorp, and specialty clinics serving populations at elevated deficiency risk. Government policy has been a foundational structural force: the Centers for Medicare and Medicaid Services (CMS) and the U.S. Preventive Services Task Force (USPSTF) together set the reimbursement and screening frameworks that determine laboratory testing volumes and procurement decisions across the entire healthcare system.

Private sector innovation has outpaced regulatory adaptation in this market. Instrument manufacturers including Abbott, Roche, and DiaSorin commercialised holoTC immunoassay kits ahead of any federal mandate requiring their adoption, creating a situation where supply-side infrastructure exists but demand-side policy has not yet compelled large-scale uptake. The market is moderately consolidated at the platform level but fragmented at the laboratory service level, with independent physician office labs and community hospitals largely continuing to order total B12 panels through legacy protocols. This structural gap between clinical capability and regulatory incentive is the defining tension of the current market and the primary variable that will determine growth velocity through 2032.

Policy-Driven Growth in the U.S. Active B12 Test Market

Three specific policy mechanisms are currently translating into measurable demand growth for active B12 testing in the United States. First, the Omnibus Budget Reconciliation Act framework governing Clinical Laboratory Improvement Amendments (CLIA) certification, administered by the Centers for Medicare and Medicaid Services under 42 CFR Part 493, requires laboratories performing high-complexity immunoassays — the category that includes most holoTC platforms — to maintain rigorous proficiency testing and personnel credentialing. This regulatory requirement concentrates active B12 testing within certified reference laboratories, increasing average order volumes per laboratory site and supporting premium pricing for validated holoTC assays over legacy total B12 panels.

Second, the National Institute on Aging's (NIA) Alzheimer's Disease Research Centers programme, operating under the National Institutes of Health (NIH) funding framework, has incorporated B12 status biomarker panels into its standardised Uniform Data Set (UDS), version 3.0, adopted across all 37 NIA-funded ADRCs. This institutional mandate directly creates sustained, protocol-driven demand for active B12 measurement within neurology and cognitive decline workup pathways. Third, the Veterans Health Administration (VHA) clinical practice guidelines for anaemia and nutritional deficiency, updated in 2022 under VHA Directive 1110.04, have expanded B12 deficiency screening criteria for veterans aged 65 and older, adding an estimated 280,000 eligible annual test encounters across the 170-facility VA Healthcare System, a captive volume directly accessible to contracted diagnostic suppliers.

Regulatory Barriers and Compliance Costs

The most consequential regulatory barrier in the U.S. active B12 test market is the absence of a dedicated Current Procedural Terminology (CPT) code for holotranscobalamin assays. The American Medical Association's CPT Editorial Panel currently classifies active B12 testing under code 82607, identical to the code used for conventional total serum B12 measurement. This coding equivalence means that hospital laboratories and independent labs receive the same CMS reimbursement rate — approximately USD 19.40 per test under the 2024 Clinical Laboratory Fee Schedule — regardless of whether they perform a clinically superior holoTC assay or a standard total cobalamin panel. The result is a structural disincentive to upgrade instrumentation and reagent contracts, directly suppressing market conversion rates in cost-sensitive laboratory environments.

A second material barrier is the FDA's 510(k) clearance pathway requirements for in vitro diagnostic devices under 21 CFR Part 880. Each new holoTC assay format — including point-of-care configurations and multianalyte panel integrations — must obtain independent 510(k) clearance from the FDA's Center for Devices and Radiological Health (CDRH), with average review timelines of six to twelve months and submission preparation costs ranging from USD 50,000 to USD 200,000 per application. For smaller reagent developers seeking to enter the active B12 space, these compliance costs create a meaningful capital requirement that reinforces the incumbent position of Abbott, Roche, and Siemens Healthineers, whose existing cleared platforms already dominate reference laboratory procurement contracts.

Policy-Created Opportunities in the U.S. Active B12 Test Market

The most immediate policy-created opportunity lies within the CMS annual wellness visit framework established under Section 4103 of the Patient Protection and Affordable Care Act (ACA). This provision mandates a covered annual wellness visit for Medicare beneficiaries, during which clinicians are required to assess and update preventive care schedules, including nutritional deficiency screenings. As of 2024, CMS serves over 65 million Medicare enrollees. Advocacy by laboratory professional societies, including the American Association for Clinical Chemistry (AACC), to incorporate active B12 testing into ACA wellness visit best practice guidelines would create a reimbursable screening pathway affecting tens of millions of annual encounters — the single largest potential volume driver in the forecast period.

A second substantial opportunity is embedded in the FDA's ongoing Real-World Evidence (RWE) programme under the 21st Century Cures Act, Section 3022, which incentivises diagnostic developers to generate post-market clinical evidence using electronic health record data. Companies that build active B12 testing into longitudinal RWE studies linked to Medicare claims data can accelerate CPT code reclassification petitions with empirical cost-effectiveness evidence, directly targeting the CMS coverage determination process administered by the Coverage and Analysis Group. A third opportunity exists within the Medicaid managed care contracting cycle: as states implement value-based payment models under Section 1115 waiver programmes, laboratory networks with demonstrated early-deficiency-detection capabilities, including active B12 testing, are positioned to negotiate quality-linked reimbursement premiums with state Medicaid agencies.

Market at a Glance

Leading Market Participants

• Abbott Laboratories
• Roche Diagnostics
• Siemens Healthineers
• DiaSorin
• Axis-Shield (now part of Alere/Abbott network)
• bioMérieux
• Beckman Coulter (Danaher)
• Quest Diagnostics
• Laboratory Corporation of America (LabCorp)
• Bio-Rad Laboratories

Regulatory and Policy Environment

The primary legislative framework governing the U.S. active B12 test market is the Clinical Laboratory Improvement Amendments of 1988 (CLIA 88), codified at 42 U.S.C. § 263a and administered jointly by CMS, the CDC, and the FDA. All laboratories performing holotranscobalamin immunoassays must hold a CLIA certificate of compliance for high-complexity testing, a designation that imposes mandatory external proficiency testing through CMS-approved programmes such as the College of American Pathologists (CAP) Surveys. Additionally, each holoTC assay platform requires FDA 510(k) clearance under the In Vitro Diagnostics regulation at 21 CFR Part 809 before commercial use in U.S. laboratories. Compared to the European Union, where the IVD Regulation (EU) 2017/746 (IVDR) mandates notified body review for Class C diagnostics — a category that includes most B12 assays — the U.S. pathway is faster for manufacturers but provides weaker post-market surveillance obligations, giving FDA-cleared platforms faster market entry than their CE-marked equivalents.

The most consequential upcoming regulatory development is the FDA's proposed rule on Laboratory Developed Tests (LDTs), published in the Federal Register in October 2023 under Docket No. FDA-2023-N-2177. If finalised as proposed, this rule will require laboratories that currently offer in-house holoTC assays under CLIA exemption to obtain full FDA 510(k) clearance within a phased four-year compliance window beginning from the rule's effective date. This change will directly impact academic medical centres and large reference laboratories — including several NIA-affiliated ADRCs — that have developed proprietary active B12 testing protocols. The compliance cost burden is expected to accelerate consolidation toward cleared commercial platforms from Abbott, Roche, and Siemens Healthineers, reshaping the competitive landscape materially by 2027.

Long-Term Policy Outlook for U.S. Active B12 Testing

By 2032, three policy shifts are expected to reshape the active B12 testing market in the United States. The FDA's LDT final rule, anticipated in full enforcement by 2028, will eliminate the majority of laboratory-developed holoTC protocols, consolidating test volumes onto FDA-cleared commercial platforms and concentrating market revenue among the three incumbent instrument manufacturers. Simultaneously, the ongoing AMA CPT Panel review cycle creates a realistic pathway for a dedicated holoTC assay code between 2026 and 2028, with the AACC and American Society for Clinical Pathology actively preparing code change request submissions. A new reimbursement code at a rate reflecting the higher analytical complexity of holoTC measurement — estimated at USD 35 to USD 45 per test — would double per-test revenue for laboratories adopting active B12 platforms.

The second wave of policy-driven change will emerge from the White House's National Strategy to Support Family Caregivers and related HHS initiatives targeting nutritional deficiency in older adults, published in 2022 under the RAISE Family Caregivers Act. As these frameworks evolve into specific screening mandates through the USPSTF recommendation development process — where a draft recommendation on nutritional deficiency screening in adults over 65 is expected between 2026 and 2028 — the active B12 test market will gain the federally endorsed clinical pathway it currently lacks. A Grade B or higher USPSTF recommendation would trigger mandatory private insurer coverage under ACA Section 2713, instantly converting active B12 from an elective to a covered preventive service across all non-grandfathered health plans and generating a step-change increase in test volumes from 2029 onward.